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sion. However, asymptomatic meniscal lesions are common and frequent
incidental ﬁndings on knee MRI of the middle-aged or older patient.
Even though meniscal lesions cannot be viewed as an innocent bystander,
its linkage with knee symptoms is complex. Other knee pathologies than
meniscus tears may often be the direct cause of knee pain. Further, the high
frequency of meniscal pathology in the general population challenges the
health professional in choosing the best treatment in the short- and long-
term. A meniscal tear can lead to knee OA by increased focal biomechanical
loading, but knee OA can also lead to meniscal tear. A degenerative menis-
cal lesion in the middle-aged or older patient could suggest early-stage
pre-radiographic knee OA and should be treated accordingly. The need for
surgical treatment of stable degenerative meniscal lesions in knees with
or without OA is often doubtful and evidence of a beneﬁcial effect above
placebo is so far lacking. Surgical resection of stable meniscal lesions is not
expected to improve meniscal functioning.
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DIETARY SUPPLEMENTS IN OA: REAL OPPORTUNITY OR UTOPIA?
A. Mobasheri
Univ. of Nottingham, Sutton Bonington, United Kingdom
Purpose: Osteoarthritis (OA) is one the most common forms of joint dis-
ease in humans and companion animals. The management of OA primarily
focuses on symptomatic pain relief using analgesics and non-steroidal
anti-inﬂammatory drugs (NSAIDs). However, pharmacotherapy with con-
ventional drugs does not inﬂuence the course of disease progression and
is associated with signiﬁcant side effects in other organ systems. Conse-
quently, there is an acute need for developing safer alternative remedies
for OA. Self-management, complementary and alternative medicine strate-
gies are receiving increasing attention from patients, practitioners and
researchers. There are many biological pathways and molecular mech-
anisms by which dietary and nutritional factors might be expected to
exert favourable inﬂuences on pathophysiological processes in cartilage
and synovium in OA. However, these are poorly understood and the quality
and consistency of research on dietary supplements and nutraceuticals has
been variable. Research in our laboratory has focussed on testing a range
of botanicals and nutritional supplements in vitro. Our current objective is
to apply high throughput post-genomic techniques to identify the major
biomarkers present in the secretome of articular cartilage and monitor
responses to pro-inﬂammatory and anti-inﬂammatory stimuli.
Methods: We have established in vitro models of canine and equine
cartilage for screening plant-derived phytochemicals such as curcumin
and cocktails of plant extracts for anti-inﬂammatory activity. Our pre-
ferred model uses cartilage explants and incorporates viability and cy-
totoxicity assays (LIVE/DEAD®) as well as glycosaminoglycan (GAG) and
prostaglandin E2 (PGE2) release assays for assessing in vitro responses
to pro-inﬂammatory cytokines, NSAIDs, nutraceuticals and plant extracts.
We have also developed high throughput proteomic techniques to map
the secretome and identify a set of biomarkers for assessing extracellular
matrix turnover.
Results: Cell viability, GAG and PGE2 release appear to be consistent and
robust parameters for assessing the safety and anti-inﬂammatory activity
of NSAIDs, plant extracts and dietary supplements on cartilage explants
in vitro. The biomarkers identiﬁed from the secretome of both species
include cartilage oligomeric matrix protein (COMP) a well established
prognostic indicator and disease marker as well as ﬁbronectin, biglycan,
chondroadherin (CHAD), matrix metalloproteinases 1 and 3 (MMP-1, MMP-
3), clusterin, decorin, thrombospondins 1 and 4 (TSP-1, TSP-4), cartilage
intermediate layer protein -1 (CILP-1) and aggrecan core protein.
Conclusions: Dietary supplementation may well have a role in inﬂuencing
the course of OA progression. However, the scientiﬁc and medical commu-
nity remains skeptical about the eﬃcacy of nutritional supplementation for
OA despite their broad acceptance and use by patients. New and innovative
approaches are needed to gain a better understanding of the response to
NSAIDs and dietary supplements that claim to have anti-inﬂammatory ac-
tivity. Our work suggests that 3-dimensional culture systems may be used
to screen for anti-inﬂammatory activity in extracts of dietary supplements.
This approach combines viability/cytotoxicity tests, biochemical assays and
proteomics. We are currently validating quantitative western blot assays
for measuring changes in the levels of the protein biomarkers identiﬁed in
the cartilage secretome in response to inﬂammatory and anti-inﬂammatory
stimuli. We are also hoping to set up multiplex assays for other inﬂamma-
tory mediators. Once established, these assays may be applied to synovial
ﬂuid and serum samples from animals on clinical or ﬁeld trials of dietary
supplements. Whether dietary supplements can be effectively and safely
recommended to reduce NSAID usage is still unclear and requires more
rigorous research. Multi-disciplinary approaches that combine hypothesis
driven and well-designed basic, clinical and epidemiological studies should
help us make better-informed decisions about the beneﬁts of dietary
supplements in OA therapy.
Our work is supported by grants from the Biotechnology and Biological
Sciences Research Council (BBSRC), the Engineering and Physical Sciences
Research Council (EPSRC), the WALTHAM Centre for Pet Nutrition, the
Wellcome Trust and the National Centre for the Replacement, Reﬁnement
and Reduction of Animals in Research (NC3Rs). The presenter gratefully ac-
knowledges the contributions of his collaborators Dr. Susan Liddell (School
of Biosciences, University of Nottingham), Dr. Julia Smith (Bruker UK) and
members of his research group, particularly Abigail Clutterbuck and Kirsty
Hillier.
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REHABILITATION: FROM BASIC SCIENCE AND BIOMECHANICS TO
CLINICAL PRACTICE
H. Bliddal, M. Henriksen
Copenhagen Univ. Hosp. Parker Inst., Frederiksberg, Denmark
The obstacles to overcome in rehabilitation of osteoarthritis must reﬂect
both the eliciting factors and practical issues with the implementation of
the program. The biomechanics of the knee may be the key to understand-
ing progression of knee OA. However, in a setting with varying degree of
joint destruction, pain, and loss of muscle strength, all three factors should
be considered by the therapist. On top of this, rehabilitation is an art of
interpersonal relationships.
It is very diﬃcult to sort out the best strategy for maintaining rehabil-
itation in patients with painful degenerative diseases [1]. The chance of
a rehabilitation program increases with the enthusiasm of both patient
and therapist. This evasive factor may to some extent be supported by
participation in a trial.
Before exercise - weight loss? While it is debated whether increased
weight per se may cause OA [2], once there, the weight seems to be
a decisive factor for progression, biomechanically driven by increased
joint loads, e.g. assesses by the knee adduction moment [3]. Weight may
inﬂuence gait by changes in peak adduction moment, muscle strength and
walking distance.
During exercise - treating the pain? To participate in e.g. exercises for a
painful disease, it must be considered whether the level of pain should
guide the therapy. This is all the more relevant as exercises may induce a
deterioration of the OA in some cases [4]. In favour of this strategy is the
central inhibition of muscle function [5]. On the other hand, reduction of
pain may cause changes in gait pattern with a potential for joint destruction
[6].
The interesting question is, whether a knee may become too bad for
exercise, i.e. if there is a ‘point-of-no-return’ for knee OA, with a unde-
sirable response in joint loading to pain at advanced stages of disease
(Henriksen et al. submitted). The interaction between structural changes,
pain, joint loadings and muscle function must be explored to improve
clinical outcomes of rehabilitation programmes.
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STATISTICAL GENETIC ANALYSES OF LARGE JOINT OA
A.M. Valdes
King’s Coll. London, London, United Kingdom
Purpose: Severe large joint osteoarthritis (OA (hip and knee) is a major
cause of and its prevalence is expected to climb as the age of the population
increases. OA is a multifactorial disease and OA cases are affected by both
genetics and environment to varying degrees. Understanding the genetic
component of OA can help uncover its molecular pathogenesis.
Methods: A review of the literature on methods which have been used to
explore the genetic contribution to large joint OA with particular emphasis
on association studies
Results: Strong familial aggregation and heritabilities have been reported
for OA at the hip, and the knee. From linkage analyses to current genome-
wide association scans a number of approaches have been used in past
decade to try to unravel the genetic component of large joint OA. Candidate
gene studies and genome-wide linkage studies have identiﬁed genes in the
bone morphogenetic pathway (GDF5 and SMAD3), the thyroid regulation
pathway (DIO2), and cell-death related pathways as involved in genetic risk
of large joint OA. Genome wide association studies have reported structural
genes (COL6A4/DVWA), inﬂammation related genes (PTGS2/PLA2G4A) and
a locus chr 7q22 associated with knee OA and two genes in the HLA
class II and class III regions (DQB1 and BTNL2). The challenges involved
in the statistical analysis of genetic data with speciﬁc emphasis on the
heterogeneity of large OA phenotypes and approaches to subphenotyping
are discussed.
Conclusions: During the coming years, as additional genetic and functional
studies further deﬁne the genetic architecture of OA and the underlying
molecular mechanisms, additional targets for novel therapies and improved
diagnostic and prognostic tests should be identiﬁed.
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IMAGING IN HAND OSTEOARTHRITIS
D. McGonagle
Leeds Univ., Leeds, United Kingdom
The hand represents a particularly useful structure for imaging OA for
many reasons including the genetic association with generalised nodal OA
and hand disease, the relatively fast onset of hand OA, especially in the
peri-menopausal period and the ability to clinically recognise disease when
conventional radiography is normal. We have used high resolution MRI to
explore early clinically evident hand OA and age related changes in the
hands in normals and also an assessment of clinically uninvolved joints
in cases with OA elsewhere. This work has been combined with cadav-
eric tissues studies to deﬁne the microanatomical basis for the observed
changes.
Whilst end stage hand OA is a disease of the whole joint it is evident that
the earliest and most striking changes are evident in the joint collateral lig-
aments in particular but also in joint capsules and tendons. These changes
including thickening, inﬂammatory changes and even complete ligament
disruption. On MRI most hand OA is erosive with these erosions being
topographically related to collateral ligaments. Likewise the position of
ligaments has been conﬁrmed as key players in the phenotypic expression
of Heberdens nodes. Prominent bone oedema at entheses is a common
feature of early hand OA and it can actually be diﬃcult to distinguish
this pattern of disease from psoriatic arthritis which is more commonly
recognised to be associated with enthesitis.
The inﬂammatory changes associated with hand OA are extensive on MRI
and appear to be centred on the capsule and extracapsular tissues to a
greater degree than the synovium. This challenges the classical view of
articular cartilage damage as the major driver in synovitis in OA. These MRI
features have been used to deﬁne a novel enthesis related joint structure
termed the synovio-entheseal complex which shows all of the histologoical
changes of OA and appears to be a ligament related mechanism of driving
synovitis in hand OA.
To date high resolution MRI imaging has permitted the conceptualisation
of a new anatomical classiﬁcation for OA based on the fact much idiopathic
hand OA is not idiopathic, at least from the anatomical site of maximal
early disease changes. The prognostic value of both MRI and ultrasound
needs to be determined in follow us studies.
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ARE GWAS STUDIES FOR OSTEOARTHRITISWORTH THE EXPENSE?
M. Warman
Children’s Hosp. Boston, Boston, MA
Forty years ago, blood group polymorphisms and other protein polymor-
phisms were the major means available to link a disease phenotype to a
gene. Thirty years ago, restriction fragment length polymorphisms detected
by Southern blotting ushered in a new era of DNA-based genetic analysis.
Twenty years ago, simple-sequence-repeat polymorphisms detected by PCR
made it possible to begin mapping hundreds of human Mendelian-genetic
diseases at reasonable cost. This PCR-based mapping coupled with the
$2,700,000,000 (U.S. taxpayer cost) Human Genome Project has culminated
in the discovery of many genes that cause human genetic disease. Over
the past decade, high-density nucleic acid array technologies have created
a new paradigm for disease-gene identiﬁcation and have provided oppor-
tunities to extend genetic analyses from patients affected with Mendelian
traits to patients affected with multifactorial diseases, such as diabetes,
obesity, mental illness, and rheumatoid arthritis. These advances are based
on the ability, in a single person and at reasonable cost, to simultaneously
query 1,000,000 common DNA variants (SNPs) distributed evenly across the
human genome. It is now reasonable to ask whether this new technology
should be applied to the study of osteoarthritis.
What have we learned from GWAS studies in other diseases? For age-
related macular degeneration and statin-induce myopathy, using fewer
than 100 cases and 100 controls, we learned that common population
variants in C3H and SLCO1B1, respectively, are strong genetic risk factors.
In contrast, for blood lipid proﬁles and for height, using greater than
100,000 participants, we learned that dozens of common variants, each
having modest to minimal effects, account for less then 25% of the genetic
variance. A priori, it was not known whether common diseases would
be inﬂuenced by few genes each with large effects, or by many genes
each with small effects. To date, most common diseases studied using
GWAS appear to fall into the latter category. Nevertheless, GWAS has
identiﬁed novel genes and pathways involved in disease processes, even
when the effect size of the common variant is small, just as rare Mendelian
genetic disorders have led to the discovery of genes and pathways whose
disease-causing variants are rare but have large effects.
Several questions are worth pondering when deciding whether GWAS
studies for OA are worth the expense. How easy is it to diagnose and
quantify osteoarthritis, compared to other complex traits? How much of
the population variance for OA is genetic? Is the genetic architecture of
OA likely to be due to a few common variants of moderate effect or
many common variants of weak effect? Is the discovery of new genes and
pathways suﬃcient reward for the expense of a GWAS study, or must
these new discoveries be “actionable,” in that they immediately improve
diagnosis or suggest new therapeutic strategies? Currently sequencing
the entire genome of an individual is twenty-times more expensive than
genotyping that individual for 1,000,000 SNPs. Therefore, for $10,000,000
is it better to perform whole genome sequencing on 1000 patients with OA
or to perform GWAS in 10,000 OA patients and 10,000 controls? We could
simply wait for sequencing costs to fall. But is the cost of waiting and not
discovering anything new greater than the cost of performing GWAS or
limited whole exome or whole genome sequencing now?
